Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised,... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Unpaywall
 
/lp/unpaywall/lapatinib-with-trastuzumab-for-her2-positive-early-breast-cancer-Dai44TqSM3

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
0140-6736
DOI
10.1016/s0140-6736(11)61847-3
Publisher site
See Article on Publisher Site

Abstract

Journal

The LancetUnpaywall

Published: Feb 1, 2012

There are no references for this article.